Selexipag
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Selexipag
Selexipag: Known uses and market status in Australia
Summary
The TxGNN model has no candidate indication with a score of 0.99 or higher for Selexipag, so there is currently no new predicted indication. The recorded uses of this drug are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 2 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| pulmonary hypertension | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| pulmonary arterial hypertension |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 12235Y | Uptravi | Tablet 400 micrograms | Valid |
Safety Considerations
- Drug Interactions: The interaction query returned 100 records. The 20 examined were all rated Moderate. Examples include:
- Vasodilators and nitrates: amyl nitrite, phentolamine, papaverine, diazoxide
- Sympathomimetics: epinephrine, ephedrine, phenylephrine
- SGLT2 inhibitors: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin
- Others: mannitol, glycerin, amifostine, deferasirox, abiraterone, acebutolol
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.